iPSC-Derived Cell Therapies Summit
Evvnt Promotion / evvnt
07.12.2021 - 09.12.2021 Virtual
Time: 9:00 am - 5:00 pm
Kongressthemen
Innovate The Next Generation of Safe, Scalable and Cost-Effective iPSC-Derived Therapies
The explosion of excitement and investment in the iPSC field has ushered in a new era of cell therapy, with these cells establishing it’s place as the optimal starting material for cell therapies targeting cancer, autoimmune, cardiac disease and much more.
Innovate The Next Generation of Safe, Scalable and Cost-Effective iPSC-Derived Therapies
The explosion of excitement and investment in the iPSC field has ushered in a new era of cell therapy, with these cells establishing it’s place as the optimal starting material for cell therapies targeting cancer, autoimmune, cardiac disease and much more.
Kongressorganizer (PCO)
Hanson Wade
Hanson Wade
Anmerkungen
Brochure: https://go.evvnt.com/853667-3?pid=4832
Speakers: Helen Tayton-Martin, CBO, Adaptimmune, Jo Brewer, Head of Allogenic Research, Adaptimmune, Andres Bratt-Leal, Co-Founder, Aspen Neuroscience and more
Brochure: https://go.evvnt.com/853667-3?pid=4832
Speakers: Helen Tayton-Martin, CBO, Adaptimmune, Jo Brewer, Head of Allogenic Research, Adaptimmune, Andres Bratt-Leal, Co-Founder, Aspen Neuroscience and more
Anfragen und Anmeldung:
https://go.evvnt.com/853667-1?pid=4832
Herr Customer Services
Allgemeinmedizin, Klinische Forschung
Sprache
Englisch
Englisch
Kongressgebühr
USD 1899.00 - USD 3597.00
USD 1899.00 - USD 3597.00
Teilnehmer erwartet
1000
1000
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."
